Filter zurücksetzen
Stichworte
AML ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

269 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

E2905 Material Submission Form NCT00843882

- 16.06.15 - 1 Formular, 5 Itemgruppen, 34 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, PART A: COMPLETED BY SUBMITTING INSTITUTIONS, B. COMPLETED BY CENTRAL LAB, Comments
E2905 Material Submission Form NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0EAADB73-1609-079C-E044-0003BA3F9857

E2902 Treatment Form - Arm A - Form 2051 NCT00093470

- 16.06.15 - 1 Formular, 8 Itemgruppen, 29 Datenelemente, 1 Sprache
Itemgruppen: Header, Vital Status, Cycle Information- First Cycle of Report Period, Cycle Information - Second Cycle of Report Period, Cycle Information - Third Cycle of Report Period, Non-Protocol Therapy, Related Forms, Comments
E2902 Treatment Form - Arm A - Form 2051 NCT00093470 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DC0913A2-D106-01B6-E034-0003BA12F5E7

E2905 Second Primary Form NCT00843882

- 16.06.15 - 1 Formular, 5 Itemgruppen, 22 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, Data amendment, Second primary cancer assessment, Comments
E2905 Second Primary Form NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0EAAC99D-1E15-00B1-E044-0003BA3F9857

E2902 Material Submission Form - Form 1845 NCT00093470

- 16.06.15 - 1 Formular, 5 Itemgruppen, 33 Datenelemente, 1 Sprache
Itemgruppen: Header, COMPLETED BY SUBMITTING INSTITUTIONS, COMPLETED BY CENTRAL LAB, Contacts, Comments
E2902 Material Submission Form - Form 1845 NCT00093470 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DBE41C5E-4D6F-6206-E034-0003BA12F5E7

E2905 Non-Protocol Therapy Form NCT00843882

- 16.06.15 - 1 Formular, 5 Itemgruppen, 27 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, Data amendment, Non-Protocol Therapy, Comments
E2905 Non-Protocol Therapy Form NCT00843882 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0EAAC4E1-8B9B-7470-E044-0003BA3F9857

NCT00093470 ECOG Acute Leukemia Disease Assessment Form - Form 1651 - NCT00093470 ECOG Acute Leukemia Disease Assessment Form - Form 1651

- 12.06.15 - 1 Formular, 3 Itemgruppen, 23 Datenelemente, 1 Sprache
Itemgruppen: Header, ECOG Acute Leukemia Assessment, Comments
NCT00093470 ECOG Acute Leukemia Disease Assessment Form - Form 1651 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DBD30C56-F431-6847-E034-0003BA12F5E7

E2906 Donor/Transplant Form NCT01041703

- 08.06.15 - 1 Formular, 7 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: ECOG clinical trial administrative data, Reporting Period, Data amendment, Vital Status, Header, Allogeneic Transplant, Footer Module
E2906 Donor/Transplant Form NCT01041703 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=842DEB36-F390-AD41-E040-BB89AD4373C4

CALGB: 10603 Lab Results - Hematology Test DRKS00003845 NCT00651261 - CALGB: 10603 Lab Results - Hematology Test NCT00651261

- 08.06.15 - 1 Formular, 6 Itemgruppen, 34 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, Lab, Lab, Differential Count, Footer Module
CALGB: 10603 Lab Results - Hematology Test NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=62302100-2333-35C1-E040-BB89AD431366

CALGB: 10603 Laboratory Normals and Units Form DRKS00003845 NCT00651261 - CALGB: 10603 Laboratory Normals and Units Form NCT00651261

- 08.06.15 - 1 Formular, 4 Itemgruppen, 20 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, Lab, Footer Module
CALGB: 10603 Laboratory Normals and Units Form NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=621DF241-3FFA-FE24-E040-BB89AD432D16

CALGB: 10603 Treatment Form DRKS00003845 NCT00651261 - CALGB: 10603 Treatment Form NCT00651261

- 08.06.15 - 1 Formular, 11 Itemgruppen, 43 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, Treatment Phase, Patient status assessment, Midostaurin/Placebo Dosing, Midostaurin/Placebo Dosing, Daunorubicin Dosing, Cytarabine Dosing, Cytarabine Dosing, Leukemia Treatment Plan, Footer Module
CALGB: 10603 Treatment Form NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=443E6AF2-2DD2-3E6F-E044-0003BA3F9857

CALGB: 10603 Follow-Up Form DRKS00003845 NCT00651261 - CALGB: 10603 Follow-Up Form NCT00651261

- 08.06.15 - 1 Formular, 10 Itemgruppen, 51 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, Treatment Phase Information, Vital Status, Disease Follow-Up Status, Notice of Progression, RECOVERY, Transplant Treatment Plan, Notice of New Primary Cancer, Footer Module
CALGB: 10603 Follow-Up Form NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=43C5D677-EB7A-6D45-E044-0003BA3F9857

LA1

- 08.06.15 - 1 Formular, 13 Itemgruppen, 24 Datenelemente, 1 Sprache
Itemgruppen: Header module, Laboratory assessments, CBC, Hematocrit, Hemoglobin, WBC, Neutrophils, Lymphocytes, Chemistry and LFT's, Creatinine, Bilirubin, AST, ALT
LA1 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF1A902D-29B1-3DEE-E034-0003BA3F9857

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video